Adicet Bio (ACET) AI Stock Analysis

• Market Cap: $79.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: N/A
• EPS Growth: 25.89%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.64
• Shares Outstanding: 9,578,474
• 10 Day Avg. Volume: 4,877,229
• 30 Day Avg. Volume: 1,918,806
• PEG Ratio: 0.19
• Price to Book (P/B): 7.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.46
• Enterprise Value/Market Cap: 14.70
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -10.76
• 1Y Price Target: $10.67
• Price Target Upside: 28.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $8.00 ▼(-3.50% Downside)

The score is held down primarily by weak financial performance (zero revenue, large losses, and substantial cash burn) and a bearish technical setup (below key moving averages with negative MACD). Corporate events provide some offset via encouraging early clinical progress and extended runway, but listing-compliance risk and the lack of supportive valuation metrics keep the overall score below average.

Positive Factors

Clinical progress: ADI-001 (autoimmune)

Robust early efficacy and a favorable safety profile supporting outpatient dosing materially improve the pathway to a pivotal trial and later commercialization. Growing enrollment across cohorts strengthens data breadth, accelerating regulatory dialogue and de‑risking the autoimmune program long term.

Extended cash runway

Proceeds from the registered direct offering extend funding into 2H 2027, reducing near‑term financing pressure and enabling execution of multiple clinical milestones and regulatory interactions without immediate dilution. This supports continuity across planned filings and pivotal trial starts.

Differentiated allogeneic γδ T‑cell platform

An off‑the‑shelf γδ CAR T platform offers potential manufacturing scalability and multi‑indication leverage. Progress toward a regulatory filing for ADI‑212 in mCRPC broadens the addressable oncology opportunity and diversifies value drivers beyond autoimmune programs.

Negative Factors

No product revenue; heavy cash burn

Persistent large losses and negative operating cash flow indicate continued reliance on external financing. This structural cash burn creates execution risk if fundraising is disrupted, pressures management to prioritize near‑term milestones, and can lead to repeated dilution over time.

Material equity decline and dilution risk

A meaningful erosion of the equity base reflects prior financings and operating deficits; coupled with large registered offerings, it signals ongoing dilution risk. Continued reliance on capital markets can compress shareholder value and limit flexibility to pursue optionality in R&D.

Listing compliance and structural governance risk

Nasdaq compliance pressure and an implemented reverse split point to structural fragility in market access; loss of listing or persistent bid‑price issues would raise the cost of capital, narrow the investor base, and impair the company’s ability to raise funds or form partnerships over the medium term.

Adicet Bio Business Overview & Revenue Model

Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

Adicet Bio primarily makes money through the development and commercialization of its allogeneic gamma delta T cell therapies for cancer treatment. The company generates revenue from partnerships and collaborations with other pharmaceutical companies, as well as through grants and funding aimed at advancing its research and development efforts. Additionally, Adicet Bio may earn income from licensing agreements, where it allows other companies to utilize its proprietary technology in exchange for upfront payments, milestone payments, and potential royalties on future products. The success of these revenue streams is significantly influenced by the company's ability to bring its therapeutic candidates to market and establish strong industry collaborations.

Adicet Bio Financial Statement Overview

Summary

Overall financial profile is weak: essentially no revenue, large ongoing net losses (TTM net loss about $115M), and heavy cash burn (TTM free cash flow about -$100M). Balance sheet leverage is modest (debt-to-equity ~0.12), but equity has fallen materially (from ~$186.6M in 2024 to ~$109.1M TTM), reinforcing funding/dilution risk.

Income Statement

Results remain deeply unprofitable, with TTM (Trailing-Twelve-Months) net loss of about $115.0M and very weak profitability (net margin roughly -18.2%). Revenue is effectively zero in 2023–TTM, and gross profit is negative in the most recent periods, highlighting limited commercial scale and ongoing cost burden. Losses have improved versus 2023 (net loss ~$142.7M) but remain large and persistent, keeping overall earnings quality and visibility low.

Balance Sheet

Leverage is modest, with TTM (Trailing-Twelve-Months) debt of ~$15.5M against equity of ~$109.1M (debt-to-equity ~0.12), which reduces near-term balance sheet risk. However, equity has declined materially from ~$186.6M in 2024 to ~$109.1M TTM, consistent with ongoing losses and potential dilution/asset drawdown. Returns on equity are strongly negative in recent periods (TTM about -0.68), indicating the capital base is not currently generating shareholder returns.

Cash Flow

Cash burn remains heavy, with TTM (Trailing-Twelve-Months) operating cash flow around -$98.4M and free cash flow around -$100.4M, implying continued reliance on funding to sustain operations. Free cash flow burn has worsened versus 2024 (about -$93.5M) even though year-over-year free cash flow growth is positive, reflecting volatility rather than durable improvement. Cash flow closely tracks net losses (free cash flow to net income ~1.02 TTM), suggesting losses are translating into real cash usage.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	24.99M	9.73M	17.90M
Gross Profit	0.00	0.00	0.00	24.99M	9.73M	17.90M
EBITDA	-108.47M	-110.65M	-136.53M	-64.70M	-60.41M	-37.41M
Net Income	-115.01M	-117.12M	-142.66M	-69.79M	-62.00M	-36.68M
Balance Sheet
Total Assets	140.48M	220.22M	207.29M	330.69M	338.94M	153.84M
Cash, Cash Equivalents and Short-Term Investments	103.10M	176.30M	159.71M	257.66M	277.54M	94.61M
Total Debt	15.54M	17.23M	20.92M	21.02M	20.94M	21.64M
Total Liabilities	31.34M	33.61M	37.12M	38.35M	35.81M	44.01M
Stockholders Equity	109.14M	186.61M	170.18M	292.34M	303.13M	109.83M
Cash Flow
Free Cash Flow	-100.36M	-93.50M	-98.18M	-61.55M	-64.10M	-42.54M
Operating Cash Flow	-98.44M	-92.38M	-93.72M	-44.77M	-51.05M	-41.55M
Investing Cash Flow	24.81M	-119.24M	-4.46M	-16.78M	-2.80M	115.22M
Financing Cash Flow	150.00K	111.31M	236.00K	41.51M	242.69M	303.00K

Adicet Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Positive. The current price of 8.29 is above the 20-day moving average (MA) of 8.04, below the 50-day MA of 9.00, and below the 200-day MA of 11.01, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 33.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACET.

Adicet Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	58 Neutral	$117.32M	-1.37	-47.96%	―	-100.00%	-17.10%
STRO	52 Neutral	$107.86M	-0.50	-1810.01%	―	-34.36%	-59.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACET	46 Neutral	$79.41M	-0.39	-71.73%	―	―	25.89%
PMVP	46 Neutral	$60.66M	-0.72	-51.87%	―	―	-58.47%
GANX	46 Neutral	$84.62M	-2.94	-261.72%	―	―	42.29%

Adicet Bio Corporate Events

Adicet Bio advances prula-cel autoimmune Phase 1 program

On January 7, 2026, Adicet Bio reported that enrollment in its Phase 1 prulacabtagene leucel (prula-cel) program in autoimmune diseases had more than doubled since October to over 20 patients as of December 31, 2025, with all seven autoimmune cohorts now actively enrolling and the first ANCA-associated vasculitis patient dosed. The company has secured U.S. FDA alignment to allow outpatient dosing of lupus nephritis and systemic lupus erythematosus patients in ongoing and future trials, is running a Phase 1 study in treatment-refractory rheumatoid arthritis to test reduced conditioning regimens, and plans multiple clinical data updates through 2026 as it works toward a pivotal trial design. Adicet is also progressing preclinical development of ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026, while an October 2025 equity raise of about $74.8 million has extended its cash runway into the second half of 2027, underpinning its ability to execute on these clinical and regulatory milestones.

The most recent analyst rating on (ACET) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Adicet Bio Implements Reverse Stock Split to Maintain Listing

On December 19, 2025, Adicet Bio’s shareholders approved, and its board subsequently set, a 1-for-16 reverse stock split of the company’s common stock, which became effective at 12:01 a.m. Eastern Time on December 30, 2025. The move reduces Adicet’s outstanding shares from roughly 153.3 million to about 9.6 million without changing the 300 million authorized share count or the stock’s par value, while proportionally adjusting equity incentive plans, options and warrants; trading on the Nasdaq Capital Market began on a split-adjusted basis under the existing “ACET” ticker on December 30, 2025, with fractional share entitlements settled in cash. By shrinking the share count and boosting the per-share trading price, the reverse split is intended to help Adicet regain compliance with Nasdaq’s minimum bid price requirement and preserve its U.S. listing, a key consideration for existing shareholders and for the company’s future access to capital markets.

The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Adicet Bio Shareholders Approve Flexible Reverse Stock Split

On December 19, 2025, Adicet Bio, Inc. held a Special Meeting of Stockholders at which investors approved an amendment to the company’s Restated Certificate of Incorporation authorizing a reverse stock split of its common shares at a ratio between one-for-five and one-for-thirty, with the exact ratio to be determined at the board’s discretion. The strong approval, with more than 111 million votes in favor and only about 2.8 million against, gave management flexibility to reduce the number of outstanding shares, a step commonly used to support compliance with stock exchange listing standards or improve the perceived value of the stock, and rendered unnecessary a contingent proposal to adjourn the meeting for further proxy solicitation.

The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.